Transgenomic Inc. (TBIO.OB) Finds Positive Profit Position on Strong Consumable and Research Services Sales
In the world of “Big Pharma,” sometimes the small things go unnoticed. Investors are so interested in when and how the product pipeline will be filled, they miss the development process required to fill it. In a certain sense, they don’t see the trees through the forest. There is much work that needs to be done before a drug gets anywhere near the sales stage, and as the drug companies often say in support of higher drug prices, it costs to get to that point. Finding a company that is a part of that process is an opportunity, and one…